Assessment of PhtD C-Terminal Immunogenicity by Opsonophagocytosis Assay (OPA) with OMVs as Adjuvants

• Main Authors: Mohammadali Malekan, Seyed Davar Siadat, Mohammadreza Aghasadeghi, Nader Shahrokhi, Sana Eybpoosh, Elnaz Afshari, Seyed fazlollah Mousavi
• Format: Article
• Language: English
• Published: Pasteur Institute of Iran 2019-12-01
• Series: Vaccine Research
• Subjects: streptococcus pneumonia; meningococcal omv; phtd; adjuvant
• Online Access: http://vacres.pasteur.ac.ir/article-1-175-en.html
• ISSN: 2383-2819; 2423-4923

Introduction: Streptococcus pneumoniae causes invasive and non-invasive diseases in children and adults. Currently, there are two types of pneumococcal vaccines: 23-valent pneumococcal polysaccharide vaccine and 13-valent pneumococcal conjugate vaccine which have caused many failures. Therefore, a new generation of pneumococcal vaccines is being pursued. Methods: An improved version of our previous study was performed using recombinant C-terminal of pneumococcal polyhistidine triad protein D (PhtD-C) as a vaccine antigen. The antigen was combined with meningococcal outer membrane vesicle (OMV) and alum as adjuvants to immunize BALB/c mice intraperitoneally. The generated total IgG, specific IgG, IgG1 and IgG2a antibodies and the killing ability of pneumococci by an opsonophagocytosis assay were then assayed. Results: Immunization by 30 µg PhtD-C and 50 µg OMV as an adjuvant, induced higher amounts of functional antibodies compared to our previous study while killing 50-55% of pneumococci cells. Conclusion: At optimized concentrations, PhtD-C and meningococcal OMV could be considered as a potent immunogens and the induced specific IgGs were effective and functional for killing pneumococci.